Bispecific Antibodies for Triple Negative Breast Cancer

被引：40

作者：

Dees, Sundee ^{[1
]}

Ganesan, Rajkumar ^{[1
]}

Singh, Sanjaya ^{[1
]}

Grewal, Iqbal S. ^{[1
]}

机构：

[1] Janssen Pharmaceut Co Johnson & Johnson, Janssen Biotherapeut, 1400 McKean Rd, Spring House, PA 19477 USA

来源：

TRENDS IN CANCER | 2021年 / 7卷 / 02期

关键词：

ACTIVATED T-CELLS; CYTOKINE RELEASE SYNDROME; PD-L1; EXPRESSION; RECEPTOR A10; BLINATUMOMAB; IMMUNOTHERAPY; CHEMOTHERAPY; LYMPHOCYTES; THERAPY;

D O I：

10.1016/j.trecan.2020.09.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple negative breast cancer (TNBC), an aggressive breast cancer subtype lacking estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expression, is associated with heightened metastatic potential and poor prognosis. While systemic chemotherapy, radiation, and surgical excision remain the current treatment modalities for patients with TNBC, the immunogenic nature of this aggressive disease has presented opportunity for the development of TNBC-targeting immunotherapies. Bispecific antibody-based therapeutics for the treatment of TNBC have gained recent attention in the scientific community. Clinical precedent has been previously established for the FDA-approved bispecific T cell engager, blinatumomab, for acute lymphoblastic leukemia. The present review discusses novel bispecific antibodies for TNBC and emerging TNBC targets for future bispecific antibody development.

引用

页码：162 / 173

页数：12

共 78 条

[1] Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes [J].

Abdollahpour-Alitappeh, Meghdad ;

Lotfinia, Majid ;

Gharibi, Tohid ;

Mardaneh, Jalal ;

Farhadihosseinabadi, Behrouz ;

Larki, Pegah ;

Faghfourian, Babak ;

Sepehr, Koushan Sineh ;

Abbaszadeh-Goudarzi, Kazem ;

Abbaszadeh-Goudarzi, Ghasem ;

Johari, Behrooz ;

Zali, Mohammad Reza ;

Bagheri, Nader .

JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (05) :5628-5642

[2]

American Cancer Society, 2019, Breast Cancer Facts Figures 2019-2020

[3] Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies [J].

Ashraf, Yahya ;

Mansouri, Hanane ;

Laurent-Matha, Valerie ;

Alcaraz, Lindsay B. ;

Roger, Pascal ;

Guiu, Severine ;

Derocq, Danielle ;

Robin, Gautier ;

Michaud, Henri-Alexandre ;

Delpech, Helene ;

Jarlier, Marta ;

Pugniere, Martine ;

Robert, Bruno ;

Puel, Anthony ;

Martin, Lucie ;

Landomiel, Flavie ;

Bourquard, Thomas ;

Achour, Oussama ;

Fruitier-Arnaudin, Ingrid ;

Pichard, Alexandre ;

Deshayes, Emmanuel ;

Turtoi, Andrei ;

Poupon, Anne ;

Simony-Lafontaine, Joelle ;

Boissiere-Michot, Florence ;

Pirot, Nelly ;

Bernex, Florence ;

Jacot, William ;

du Manoir, Stanislas ;

Theillet, Charles ;

Pouget, Jean-Pierre ;

Navarro-Teulon, Isabelle ;

Bonnefoy, Nathalie ;

Pelegrin, Andre ;

Chardes, Thierry ;

Martineau, Pierre ;

Liaudet-Coopman, Emmanuelle .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7

[4] Expression of Tumour-Associated MUC1 Is a Poor Prognostic Marker in Breast Cancer in Kumasi, Ghana [J].

Atta Manu, E. ;

Bedu-Addo, K. ;

Titiloye, N. A. ;

Ameh-Mensah, C. ;

Opoku, F. ;

Duduyemi, B. M. .

JOURNAL OF ONCOLOGY, 2020, 2020

[5] Bispecific T-Cell Engaging Antibodies for Cancer Therapy [J].

Baeuerle, Patrick A. ;

Reinhardt, Carsten .

CANCER RESEARCH, 2009, 69 (12) :4941-4944

[6]

Bergin Alice R T, 2019, F1000Res, V8, DOI 10.12688/f1000research.18888.1

[7] Activated T cells armed with bispecific antibodies kill tumor targets [J].

Bhutani, Divaya ;

Lum, Lawrence G. .

CURRENT OPINION IN HEMATOLOGY, 2015, 22 (06) :476-483

[8] Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells [J].

Chang, Chien-Hsing ;

Wang, Yang ;

Li, Rongxiu ;

Rossi, Diane L. ;

Liu, Donglin ;

Rossi, Edmund A. ;

Cardillo, Thomas M. ;

Goldenberg, David M. .

CANCER RESEARCH, 2017, 77 (19) :5384-5394

[9] Reprogramming Exosomes as Nanoscale Controllers of Cellular Immunity [J].

Cheng, Qnqin ;

Shi, Xiaojing ;

Han, Menglu ;

Smbatyan, Goar ;

Lenz, Heinz-Josef ;

Zhang, Yong .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2018, 140 (48) :16413-16417

[10]

Dai XF, 2015, AM J CANCER RES, V5, P2929

← 1 2 3 4 5 6 7 8 →